Blakey DC - Search Results

1

Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.

Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ. Blakey DC, et al. Clin Cancer Res. 2002 Jun;8(6):1974-83. Clin Cancer Res. 2002. PMID: 12060643

2

ZD6126: a novel small molecule vascular targeting agent.

Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. Blakey DC, et al. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1497-502. doi: 10.1016/s0360-3016(02)03922-6. Int J Radiat Oncol Biol Phys. 2002. PMID: 12459377

3

ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA. Davis PD, et al. Among authors: blakey dc. Cancer Res. 2002 Dec 15;62(24):7247-53. Cancer Res. 2002. PMID: 12499266

4

Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC. Evelhoch JL, et al. Among authors: blakey dc. Clin Cancer Res. 2004 Jun 1;10(11):3650-7. doi: 10.1158/1078-0432.CCR-03-0417. Clin Cancer Res. 2004. PMID: 15173071

5

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging.

Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, Ashton SE, Ryan AJ, Blakey DC, Waterton JC. Robinson SP, et al. Among authors: blakey dc. Br J Cancer. 2003 May 19;88(10):1592-7. doi: 10.1038/sj.bjc.6600926. Br J Cancer. 2003. PMID: 12771928 Free PMC article.

6

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.

Fens MH, Hill KJ, Issa J, Ashton SE, Westwood FR, Blakey DC, Storm G, Ryan AJ, Schiffelers RM. Fens MH, et al. Among authors: blakey dc. Br J Cancer. 2008 Oct 21;99(8):1256-64. doi: 10.1038/sj.bjc.6604675. Epub 2008 Sep 16. Br J Cancer. 2008. PMID: 18797467 Free PMC article.

7

Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model.

McIntyre DJ, Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Blakey DC, Peers IS, Waterton JC. McIntyre DJ, et al. Among authors: blakey dc. Neoplasia. 2004 Mar-Apr;6(2):150-7. doi: 10.1593/neo.03247. Neoplasia. 2004. PMID: 15140404 Free PMC article.

8

Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.

Robinson SP, Kalber TL, Howe FA, McIntyre DJ, Griffiths JR, Blakey DC, Whittaker L, Ryan AJ, Waterton JC. Robinson SP, et al. Among authors: blakey dc. Neoplasia. 2005 May;7(5):466-74. doi: 10.1593/neo.04622. Neoplasia. 2005. PMID: 15967099 Free PMC article.

9

Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.

Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S. Goto H, et al. Among authors: blakey dc. Clin Cancer Res. 2004 Nov 15;10(22):7671-6. doi: 10.1158/1078-0432.CCR-04-1171. Clin Cancer Res. 2004. PMID: 15570000

10

Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.

Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S. Goto H, et al. Among authors: blakey dc. Cancer Res. 2002 Jul 1;62(13):3711-5. Cancer Res. 2002. PMID: 12097279

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters